MUSTANG BIO, INC. — fact timeline

MUSTANG BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 15, 2026, Mustang Bio, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Staff notice has no immediate effect on the listing of the Compan”

Manuel Litchman was appointed as Interim Chief Financial Officer at MUSTANG BIO, INC..

“On November 15, 2024, the Company’s Board of Directors (the “Board”) appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company’s Interim Chief Financial Officer, effective immediately.”

James Murphy resigned as Interim Chief Financial Officer at MUSTANG BIO, INC..

“On November 12, 2024, James Murphy resigned as the Company’s Interim Chief Financial Officer.”

David Jin was appointed as Director at MUSTANG BIO, INC..

“On October 23, 2024, the Board of Directors (the “Board”) of the Company increased the number of directors on the Board from six to seven and appointed David Jin as a new member of the Board.”

MUSTANG BIO, INC. amended Warrant Amendment Agreement with the Investor (effective 2024-04-29).

“onnection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.”

MUSTANG BIO, INC. entered into Purchase Agreement with a certain institutional investor (effective 2024-04-29).

“the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”).”

MUSTANG BIO, INC. reported preliminary financial results for the three months ended March 31, 2024.

“Based on information currently available, we estimate that as of March 31, 2024, cash and cash equivalents were approximately $1.3 million, and cash used in operating activities for the first quarter of 2024 was $5.3 million.”

MUSTANG BIO, INC. announced a restructuring with charges of approximately $0.2 million (approximately 81% of its employee base).

“to be substantially completed in the second quarter of 2024. As a result of these actions, Mustang expects to incur personnel-related restructuring charges of approximately $0.2 million in connection with one-time employee termination cash expenditures, which are expected to be incurred in the second quarter of 2024. Mustang may also incur other charges or cash”

MUSTANG BIO, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 13, 2024, Mustang Bio, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Annual Report on F”

MUSTANG BIO, INC. reported the fiscal year ended December 31, 2023 results: net income $51.6 million, EPS $6.00 per share.

“On March 11, 2024, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2023.”

James Murphy was appointed as Interim Chief Financial Officer at MUSTANG BIO, INC..

“On January 19, 2024, Mustang Bio, Inc. (the “Company”) appointed James Murphy as the Company’s Interim Chief Financial Officer.”